학술논문
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial
Document Type
Article
Author
Source
In: Frontiers in Immunology . (Frontiers in Immunology, 2023, 14)
Subject
Language
English
ISSN
16643224